{"product_id":"iconplc-business-model-canvas","title":"ICON (Ireland) Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Business Model Canvas for an Irish CRO — ready-to-use, investor-grade blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind ICON (Ireland)'s business model in a concise, actionable Business Model Canvas—revealing customer segments, key partners, revenue levers and growth risks. Ideal for investors, consultants and founders who need a ready-to-use tool; download the complete Word\/Excel canvas to benchmark and execute the strategy today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal pharma and biotech sponsors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eICON collaborates with large and mid-cap pharma and biotech firms to design and run end-to-end clinical programs, underpinning steady study pipelines and multi-year master service agreements worth billions; in 2024 ICON reported approximately $3.96 billion in revenue. Joint governance models align milestones, risk-sharing and quality metrics across programs. Long-term sponsor relationships drive repeat business and enable portfolio-level optimization and resource planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical device and diagnostics companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eICON partners with medical device and diagnostics companies to generate pre- and post-market clinical evidence, supporting usability, PMS and real-world performance studies across 40+ countries. Co-developing regulatory strategies reduces time-to-CE\/510(k)\/PMA and mitigates MDR compliance risks. Integrated service models bundle biostatistics, data management and vigilance for end-to-end device support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSites, investigators, and patient networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eICON leverages trusted site networks and KOLs to accelerate start-up and enrollment, cutting site activation timelines by ~30% and addressing the industry-wide issue that about 80% of trials face enrollment delays; preferred site partnerships boost feasibility, data quality, and protocol adherence by improving visit completion and query resolution rates. Patient advocacy groups and registries expand access to rare\/diverse cohorts, while digital recruitment partners can reduce screen failure rates by ~20% and broaden reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and data platform providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlliances with eClinical, EDC, eCOA, eSource and wearables vendors enable ICON's decentralized and hybrid trials, with ~60% of global sponsors using DCT elements by 2024; EMR\/EHR and RWD integration has increased usable clinical evidence coverage by ~40%. Interoperable, validated platforms shorten study builds and cut CRA monitoring burden by up to 30%, while joint AI\/ML roadmaps advance risk-based monitoring and predictive safety.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartners: eClinical, EDC, eCOA, eSource, wearables\u003c\/li\u003e\n\u003cli\u003eData: EMR\/EHR, RWD, analytics\u003c\/li\u003e\n\u003cli\u003eImpact: ~60% DCT adoption (2024), ~40% more evidence, ≤30% CRA time\u003c\/li\u003e\n\u003cli\u003eInnovation: AI\/ML-enabled monitoring \u0026amp; risk mgmt roadmaps\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory bodies and standards organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eICON Ireland engages proactively with FDA, EMA, MHRA and PMDA to shape compliant trial designs, leveraging EMA parallel consultation and scientific advice to de-risk submissions; MDR has applied since 26 May 2021 and 21 CFR Part 11 governs electronic records in the US, while ICH-GCP remains the global ethical standard.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory engagement: EMA parallel consults\u003c\/li\u003e\n\u003cli\u003eStandards: ICH-GCP, 21 CFR Part 11, MDR (in force 26-05-2021)\u003c\/li\u003e\n\u003cli\u003eOutcomes: early advice reduces submission risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartners accelerate DCT-enabled trials — site activation \u003cstrong\u003e30%\u003c\/strong\u003e, CRA time ≤\u003cstrong\u003e30%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eICON Ireland's partners—pharma\/biotech, device firms, site networks\/KOLs, eClinical vendors and regulators—drive multiyear MSAs, repeat programs and DCT-enabled trials; ICON reported $3.96B revenue in 2024. Partnerships cut site activation ~30%, reduce screen failures ~20%, support ~60% DCT adoption and ~40% more usable RWD while trimming CRA time ≤30%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 Impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\/Biotech\u003c\/td\u003e\n\u003ctd\u003eMSAs, program delivery\u003c\/td\u003e\n\u003ctd\u003e$3.96B revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites\/KOLs\u003c\/td\u003e\n\u003ctd\u003eEnrollment accel.\u003c\/td\u003e\n\u003ctd\u003e~30% faster start-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eeClinical\/vendors\u003c\/td\u003e\n\u003ctd\u003eDCT \u0026amp; data\u003c\/td\u003e\n\u003ctd\u003e~60% DCT use, ≤30% CRA time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulators\u003c\/td\u003e\n\u003ctd\u003eAdvice \u0026amp; de-risk\u003c\/td\u003e\n\u003ctd\u003eEMA\/US\/UK consults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for ICON (Ireland) that maps customer segments, channels, value propositions, revenue streams, key activities, partners, resources, cost structure and customer relationships with real-world detail. Designed for presentations and funding discussions, it includes competitive-advantage analysis, SWOT-linked insights and validation support for entrepreneurs, analysts and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of ICON (Ireland)’s business model with editable cells—quickly pinpoint outsourcing, clinical-trial and service gaps. Shareable, boardroom-ready snapshot that saves hours and streamlines strategic alignment across teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial design and operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eICON plans protocols, oversees start-up, manages sites and monitors execution across phases I–IV, applying risk-based monitoring and quality-by-design to cut cycle times and deviations (up to 20% in recent programs), coordinating operations across 90+ countries to maintain consistent standards and on-time delivery amid a global CRO market ≈USD 60B in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData management, biostatistics, and analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2024 ICON Ireland captures, cleans and analyzes clinical data at scale across global trials, using centralized ETL pipelines and validated CDMS. Biostatisticians draft SAPs and deliver CSR-ready outputs conforming to ICH E3 standards. Advanced analytics enable interim looks and adaptive designs with real-time dashboards. Robust data governance, aligned with GDPR and GCP, safeguards integrity and compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory strategy and submissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eICON develops regulatory roadmaps and health authority engagement plans, compiling modules, managing eCTD publishing and coordinating responses to shorten approval timelines. Regional experts across 40+ countries navigate country-specific requirements and supported 3,200 regulatory submissions in 2024. These services reduced average approval timelines by about 25% and mitigated rejection risk through proactive dossier management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient recruitment and retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eICON Ireland drives enrollment velocity through targeted outreach and feasibility assessments, using digital prescreening and decentralized visits to reduce patient burden and site load. Retention programs — reminder systems, home visits and remote monitoring — sustain protocol adherence and visit completion. Diversity strategies expand recruitment channels to improve representativeness and evidence generalizability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargeted outreach: feasibility-led enrollment\u003c\/li\u003e\n\u003cli\u003eDecentralized tools: lower patient burden\u003c\/li\u003e\n\u003cli\u003eRetention programs: maintain adherence\u003c\/li\u003e\n\u003cli\u003eDiversity: broaden representation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSafety, pharmacovigilance, and post-market studies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eICON (Ireland) monitors safety signals and manages case processing and reporting through its global PV network, processing over 1 million ICSRs annually and supporting regulatory submissions. It conducts PASS, disease registries and RWE post-approval studies to generate real-world safety and effectiveness evidence. Signal detection and benefit-risk assessments drive labeling updates and lifecycle management to sustain market access; ICON employed ~15,000 staff in 2024 and reported ~4.1B USD revenue in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePV volume: \u0026gt;1,000,000 ICSRs\/yr\u003c\/li\u003e\n\u003cli\u003eStudy types: PASS, registries, RWE\u003c\/li\u003e\n\u003cli\u003e2024 employees: ~15,000\u003c\/li\u003e\n\u003cli\u003e2024 revenue: ~4.1B USD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal CRO in \u003cstrong\u003e90+\u003c\/strong\u003e countries, \u003cstrong\u003e20%\u003c\/strong\u003e faster cycles, \u003cstrong\u003eUSD 4.1B\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eICON Ireland designs and runs global trials across 90+ countries, cutting cycle times and deviations up to 20% and operating in a ~USD 60B CRO market (2024). It delivers centralized data capture\/analysis, 3,200 regulatory submissions (2024) and \u0026gt;1,000,000 ICSRs\/yr, supporting post‑approval RWE and PV. The firm employed ~15,000 staff and reported ~USD 4.1B revenue in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e90+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eUSD 4.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e~15,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReg submissions\u003c\/td\u003e\n\u003ctd\u003e3,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICSRs\/yr\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,000,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the exact ICON (Ireland) Business Model Canvas file, not a mockup or sample. When you purchase, you’ll receive this same complete document in editable formats ready for editing and presenting. No placeholders or surprises—what you see is what you’ll download and use immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674934395257,"sku":"iconplc-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/iconplc-business-model-canvas.png?v=1755799019","url":"https:\/\/portersfiveforce.com\/products\/iconplc-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}